Expression of prostate-specific antigen and prostate-specific membrane antigen transcripts in blood cells: implications for the detection of hematogenous prostate cells and standardization.
Circulating prostate cells can be detected in cancer patients by using reverse transcriptase-PCR (RT-PCR) assay for prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSM) mRNA. A quality-control study involving a conventional RT-PCR assay was performed and, surprisingly, detected both transcripts in many negative control cell lines and in normal blood samples. The existence of an illegitimate transcription of the PSA and PSM genes was evidenced by sequence analysis of several PSM and PSA-PCR products. Sequencing indeed demonstrated the presence of a PSA or PSM polymorphism in some but not all the cell lines and patient samples, as well as a heterozygous mutation (G to A; Asp to Asn) in the Jurkat cell line. Moreover, the amount of PSA transcript in MCF-7, a PSA-negative breast line, increased after incubation with cycloheximide. Interestingly, the frequency of positivity was as high as 12% in male samples if only tested once, but dropped to 3% upon multiple testing of the same cDNA. This highlights the stochastic effects in RT-PCR results at high sensitivity, hence the importance of repetitive testing in clinical samples. Decreasing the number of cycles avoided the amplification of illegitimate transcripts but also affected the limit of detection, as evidenced with PSA and PSM cDNA containing plasmids, mixing of LNCap with normal blood samples, and the PSA-PSM-negative K562 cell line. The current data raise the need for a multicentric standardization of the RT-PCR methodology used to amplify PSA and PSM transcripts.
Gala
J L
JL
Department of Biochemistry, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Bruxelles, Belgique. gala@sang.ucl.ac.be
Heusterspreute
M
M
Loric
S
S
Hanon
F
F
Tombal
B
B
Van Cangh
P
P
De Nayer
P
P
Philippe
M
M
D000328:Adult; D000368:Aged; D000818:Animals; D000954:Antigens, Surface / Q000096:biosynthesis / Q000097:blood; D001773:Blood Cells / Q000378:metabolism*; D001943:Breast Neoplasms; D016466:CHO Cells; D002268:Carboxypeptidases / Q000096:biosynthesis* / Q000097:blood / Q000235:genetics; D002460:Cell Line; D002461:Cell Line, Transformed; D006224:Cricetinae; D003513:Cycloheximide / Q000494:pharmacology; D017931:DNA Primers; D005091:Exons; D005260:Female; D043425:Glutamate Carboxypeptidase II; D006579:Heterozygote; D006801:Humans; D019169:Jurkat Cells; D008297:Male; D008875:Middle Aged; D017354:Point Mutation; D016133:Polymerase Chain Reaction / Q000379:methods; D011110:Polymorphism, Genetic; D017430:Prostate-Specific Antigen / Q000096:biosynthesis* / Q000097:blood / Q000235:genetics; D011471:Prostatic Neoplasms; D011994:Recombinant Proteins / Q000096:biosynthesis; D012680:Sensitivity and Specificity; D013269:Stochastic Processes; D014158:Transcription, Genetic / Q000187:drug effects; D014162:Transfection; D014407:Tumor Cells, Cultured
D000954:Antigens, Surface; D017931:DNA Primers; D011994:Recombinant Proteins; D003513:Cycloheximide; D002268:Carboxypeptidases; C473848:FOLH1 protein, human; D043425:Glutamate Carboxypeptidase II; D017430:Prostate-Specific Antigen